Morgan Stanley Initiates Coverage on Zealand Pharma A/S (NASDAQ:ZEAL)

Morgan Stanley began coverage on shares of Zealand Pharma A/S (NASDAQ:ZEALGet Rating) in a research report report published on Friday, The Fly reports. The brokerage issued an overweight rating on the stock.

Zealand Pharma A/S Stock Up 7.7 %

NASDAQ ZEAL opened at $19.09 on Friday. The company has a debt-to-equity ratio of 0.93, a current ratio of 4.79 and a quick ratio of 4.78. Zealand Pharma A/S has a 1 year low of $9.93 and a 1 year high of $34.30. The business’s 50-day moving average is $17.16 and its 200 day moving average is $14.61.

Institutional Trading of Zealand Pharma A/S

An institutional investor recently raised its position in Zealand Pharma A/S stock. Bank of America Corp DE raised its position in shares of Zealand Pharma A/S (NASDAQ:ZEALGet Rating) by 46.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 221,369 shares of the company’s stock after acquiring an additional 70,423 shares during the quarter. Bank of America Corp DE owned approximately 0.51% of Zealand Pharma A/S worth $3,442,000 at the end of the most recent quarter. Institutional investors own 1.73% of the company’s stock.

Zealand Pharma A/S Company Profile

(Get Rating)

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management.

Featured Stories

The Fly logo

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with's FREE daily email newsletter.